Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/180635
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCanaslan, Sezgi-
dc.contributor.authorSchmitz, Matthias-
dc.contributor.authorVillar Piqué, Anna-
dc.contributor.authorMaass, Fabian-
dc.contributor.authorGmitterová, Karin-
dc.contributor.authorVarges, Daniela-
dc.contributor.authorLingor, Paul-
dc.contributor.authorLlorens Torres, Franc-
dc.contributor.authorHermann, Peter-
dc.contributor.authorZerr, Inga-
dc.date.accessioned2021-10-18T07:25:10Z-
dc.date.available2021-10-18T07:25:10Z-
dc.date.issued2021-09-22-
dc.identifier.urihttp://hdl.handle.net/2445/180635-
dc.description.abstractAlpha-synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases. A diagnosis may be challenging because clinical symptoms partially overlap, and there is currently no reliable diagnostic test available. Therefore, we aimed to identify a suitable marker protein in cerebrospinal fluid (CSF) to distinguish either between different types of alpha-synucleinopathies or between alpha-synucleinopathies and controls. In this study, the regulation of different marker protein candidates, such as alpha-synuclein (a-Syn), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (tau) in different types of alpha-synucleinopathies, had been analyzed by using an ultrasensitive test system called single-molecule array (SIMOA). Interestingly, we observed that CSF-NfL was significantly elevated in patients with DLB and MSA compared to patients with PD or control donors. To differentiate between groups, receiver operating characteristic (ROC) curve analysis resulted in a very good diagnostic accuracy as indicated by the area under the curve (AUC) values of 0.87-0.92 for CSF-NfL. Furthermore, we observed that GFAP and tau were slightly increased either in DLB or MSA, while a-Syn levels remained unregulated. Our study suggests NfL as a promising marker to discriminate between different types of alpha-synucleinopathies or between DLB/MSA and controls.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFrontiers Media SA-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fnagi.2021.717930-
dc.relation.ispartofFrontiers in Aging Neuroscience, 2021, vol. 13 num. 717930-
dc.relation.urihttps://doi.org/10.3389/fnagi.2021.717930-
dc.rightscc by (c) Canaslan, Sezgi et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationLíquid cefalorraquidi-
dc.subject.classificationMalalties neurodegeneratives-
dc.subject.otherCerebrospinal fluid-
dc.subject.otherNeurodegenerative Diseases-
dc.titleDetection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-10-14T08:46:33Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid34630068-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
fnagi-13-717930.pdf2.14 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons